CMPK1 and neoplasm: Mutations in UMP/CMPK1 responsible for CDV-resistance have been selected and characterized in HPV(+) tumor cells and, to our knowledge, it is the first time that this enzyme has been involved in resistance against an antiviral or an anticancer drug, in vitro or in vivo.